Sylvester Comprehensive Cancer Center

The research offers an early view into challenges that health systems across the globe will likely face as extreme heat becomes more common.

Researchers found machine learning models using patient-reported outcomes and clinical data could help forecast unplanned health care use after treatment.

Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus.

A large U.S. study showed that adults who have never been married face a significantly higher risk of developing cancer than those who have been married.

A study identified genetic mutations tied to earlier diagnosis and faster progression of myelodysplastic syndromes.

Serial liquid biopsies consistently showed AR alterations linked to poorer outcomes, and findings support “real-time” molecular testing to guide personalized care.

The new facility doubles Sylvester’s research footprint, breaking down barriers between scientific research and patient care.

A study from Sylvester Cancer Center suggests that blocking p300 may help resensitize cancer cells to chemotherapy.

Two gene mutations, IDH2 and SRSF2, work together to disrupt RNA editing, changing how blood cells develop in acute myeloid leukemia

A new study presented at the 2025 ASH Annual Meeting revealed that subtle disruptions in genome architecture can predispose individuals to lymphoma.

Researchers at Sylvester Comprehensive Cancer Center lead the way in innovative AML treatments.

The novel targeted drug olutasidenib has been shown to be effacacious in select patients with MDS.

New study takes a deep dive into how TAF1 operates to promote development of new blood cells.

Two new tumor profiling studies offer insights into how to classify such brain tumors and how they evolve after treatment.

Sylvester Comprehensive Cancer Center has opened a clinical trial for patients with high-grade neuroendocrine cancers evaluating an oncolytic virus.

Scientists from Sylvester Comprehensive Cancer Center have found that targeting ZNF638 can induce an antiviral response in glioblastoma.

Sylvester researchers recently published positive data on a new treatment regimen for patients with relapsed or refractory follicular lymphoma.

A person’s “biological age” may be a hidden factor in their risk of colorectal cancer before the age of 50.

Racial/ethnic minorities are often diagnosed with lung cancer at later stages than White patients but that disadvantage is smaller in Hispanic populations.

Steven Chen, PhD, and colleagues identified a 10-gene biomarker that may predict benefit with adjuvant chemotherapy in stage II/III colon cancer.

Estelamari Rodriguez, MD, MPH, is breaking down barriers to care by creating Spanish-language content about lung cancer for patients and caregivers.

According to a study published in Blood Neoplasia, standard-of-care treatment for acute myeloid leukemia is safe and effective for adults over 80.

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine announced the formation of the Sylvester Brain Tumor Institute.

Brandon Mahal, MD, of Sylvester Comprehensive Cancer Center, was commissioned to write a collaborative article on prostate cancer for The Lancet.

Two new grants from the U.S. Department of Defense will support Sylvester Comprehensive Cancer Center studies of endometrial cancer in Black women.

A study by Sylvester Comprehensive Cancer Center assessed the outcomes of a community-based effort to test for and eradicate H. pylori, a major risk factor for gastric cancer.

In a new phase 3 clinical trial, imetelstat demonstrated clear advantages for patients who have failed or are ineligible for other therapies.

Sylvester Comprehensive Cancer Center and NANETS will present a regional educational conference focusing on neuroendocrine tumors.

Damian Green, MD, will join Sylvester Comprehensive Cancer Center this spring to lead its transplantation and cellular therapy services.

Some head and neck cancers may respond to the drug olaparib or the combination of olaparib with decitabine.